Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer

Julien Faget1, Svenja Groeneveld1, Gael Boivin2

  • 1Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.

Cell Reports
|December 16, 2017
PubMed

Insights

Tumor-infiltrating neutrophils (Gr1+ cells) promote lung cancer growth and hinder anti-PD1 immunotherapy by creating a hypoxic microenvironment. This creates a detrimental cycle involving neutrophils and Snail, impacting cancer progression.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • Tumor immune microenvironment characterization is crucial for novel cancer therapy development.
  • Neutrophils represent a significant component of the tumor immune infiltrate.
  • Understanding neutrophil roles in lung cancer is essential for therapeutic strategies.

Purpose of the Study:

  • To investigate the role of Gr1+ neutrophils in Kras(G12D)-driven lung cancer progression.
  • To elucidate the mechanisms by which neutrophils impact anti-PD1 immunotherapy efficacy.
  • To identify key molecular interactions within the tumor microenvironment.

Main Methods:

  • Utilized a Kras(G12D)-driven mouse model of lung cancer.
  • Performed Gr1+ cell depletion experiments.
  • Analyzed T cell homing, angiogenesis, hypoxia, and gene expression (Snail, Cxcl2).

Main Results:

  • Gr1+ neutrophils were found to promote tumor growth and impede anti-PD1 immunotherapy.
  • Neutrophils altered angiogenesis, induced hypoxia, and sustained Snail expression in cancer cells.
  • A positive feedback loop was identified where Snail-expressing cells increase Cxcl2 secretion, further recruiting neutrophils.

Conclusions:

  • Gr1+ neutrophils play a critical role in promoting lung cancer progression and resistance to immunotherapy.
  • A Snail-neutrophil feedback loop sustains a pro-tumorigenic microenvironment.
  • Targeting this neutrophil-Snail axis may offer a novel therapeutic strategy for lung cancer.